サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574936

直接作用型抗ウイルス薬市場：タイプ別、適応症別、投与経路別、流通別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

Direct-acting Antiviral Drug Market, By Type, By Indication, By Route of Administration, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
直接作用型抗ウイルス薬市場：タイプ別、適応症別、投与経路別、流通別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

直接作用型抗ウイルス薬市場規模は2023年に284億932万米ドルとなり、2024年から2032年にかけてCAGR 5.50%で拡大

直接作用型抗ウイルス薬市場- 市場力学

肝炎とHIVに対する認識とスクリーニングプログラムの高まり

直接作用型抗ウイルス薬（DAA）市場は、肝炎やHIV感染の有病率の増加など、いくつかの主要な要因によって拡大しています。これらの疾患に対する認識が高まるにつれ、検診を受ける人が増え、診断率の上昇につながっています。ヘルスケアへのアクセス改善やこれらの疾患に関する教育も一因となっています。さらに、最近の医薬品開発の動向により、より効果的で即効性のある治療薬が開発され、高い注目を集めています。

米国疾病予防管理センター（CDC）は、2021年にはB型およびC型肝炎患者の約25％が診断されると報告しており、効果的な治療法の緊急の必要性が浮き彫りになっています。このような意識の高まりとスクリーニングプログラムの改善は、ウイルス感染を効果的に管理・治療する上で極めて重要です。その結果、DAAに対する需要は増加の一途をたどり、抗ウイルス治療の将来を形作ることになります。

直接作用型抗ウイルス薬市場-主な洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）にCAGR約5.50%で毎年成長すると推定されます。

タイプ別では、NS5Aタンパク質が2023年に最大の市場シェアを示すと予測されています。

適応症別では、2023年にはC型肝炎ウイルスが主要タイプとなっています。

投与経路別では、経口剤が2023年の主要タイプでした。

流通別では、2023年には病院薬局が主要タイプとなっています。

地域別では、北米が2023年の売上高でトップ

直接作用型抗ウイルス薬市場-セグメンテーション分析：

直接作用型抗ウイルス薬の世界市場は、タイプ、適応症、投与経路、流通、地域に基づいてセグメント化されます。

市場はタイプにより3つのカテゴリーに分けられる：NS3/4A Protease、NS5A Protein、NS5B RNA-Dependent RNA Polymeraseです。NS5A Proteinセグメントは、直接作用型抗ウイルス薬市場で最も顕著です。NS5A阻害剤はC型肝炎の治療に非常に有効であり、多くの成功した治療レジメンに使用されているからです。NS5A阻害薬はウイルスの複製と集合を阻害し、患者の予後を改善します。NS5A阻害剤を含む併用療法への需要が高まっていることから、このセグメントは優位を占めています。その結果、NS5Aプロテイン医薬品はC型肝炎治療の選択肢を広げ、患者の健康状態を改善する上で極めて重要な存在となっています。

市場は適応症によって4つのカテゴリーに分類される：C型肝炎ウイルス、HIV感染/AIDS、インフルエンザ、予防薬です。C型肝炎ウイルスセグメントは、直接作用型抗ウイルス薬市場で最も顕著です。C型肝炎は世界中で数百万人が罹患しており、効果的な治療に対する強い需要が生じているからです。C型肝炎に特化した直接作用型抗ウイルス薬は高い治癒率を示しており、広く使用されています。C型肝炎の認知度が高まるにつれて、これらの治療を求める患者も増え、このセグメントが主流となっています。全体として、C型肝炎治療薬は、健康状態を改善し、病気の蔓延を抑える上で重要な役割を果たしています。

直接作用型抗ウイルス薬市場-地理的洞察

直接作用型抗ウイルス薬（DAA）市場は、C型肝炎とHIVの効果的な治療に対する需要が高い北米、特に米国が最大です。欧州がこれに続き、ドイツ、フランス、英国などが抗ウイルス療法に投資しています。アジア太平洋は、特に中国やインドのような国々で、医療に対する認識とアクセスが高まっており、急成長している地域です。ラテンアメリカも、ウイルス感染症対策を目的としたヘルスケアへの取り組みが活発化しており、可能性を示しています。中東とアフリカの市場シェアは小さいが、ヘルスケアインフラの改善により徐々に拡大しています。全体としては北米がリードしているが、他の地域もDAA市場で大きく前進しています。

直接作用型抗ウイルス薬市場-競合情勢：

直接作用型抗ウイルス薬（DAA）市場は、C型肝炎やHIVの効果的な治療で知られるギリアドサイエンシズやアッヴィなどの大手企業が牽引しています。メルク社やブリストルマイヤーズスクイブ社などの他の企業も、競争力を維持するために技術革新と研究に注力し、様々な抗ウイルス薬の選択肢を提供しています。多くの企業が製品ラインを強化し、より広い市場に参入するためにパートナーシップを結んでいます。特許が切れると、マイランやヘテロ・ラボのようなジェネリック医薬品メーカーが参入し、より低価格の代替品を提供するようになります。市場は世界的に拡大しており、手頃な価格で治療を受けられるようにすることが重視されています。企業は規制上の課題に直面しており、承認には大規模な臨床試験が必要です。全体として、この情勢はダイナミックであり、激しい競合と患者ケアの改善への取り組みが特徴です。

目次

第1章 直接作用型抗ウイルス薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 直接作用型抗ウイルス薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 直接作用型抗ウイルス薬産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 直接作用型抗ウイルス薬市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 直接作用型抗ウイルス薬市場情勢

  • 直接作用型抗ウイルス薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 直接作用型抗ウイルス薬市場- タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • NS3/4Aプロテアーゼ
    • NS5Aタンパク質
    • NS5B RNA依存性RNAポリメラーゼ

第8章 直接作用型抗ウイルス薬市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • C型肝炎ウイルス
    • HIV感染/エイズ
    • インフルエンザ
    • 予防

第9章 直接作用型抗ウイルス薬市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 静脈内
    • 経口
    • 皮下
    • 外用

第10章 直接作用型抗ウイルス薬市場- 流通別

  • 概要
    • 流通別セグメントシェア分析
    • 病院薬局
    • オンラインドラッグストア
    • 小売薬局

第11章 直接作用型抗ウイルス薬市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 直接作用型抗ウイルス薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Gilead Sciences
    • AbbVie
    • Merck &Co.
    • Bristol-Myers Squibb
    • Johnson &Johnson
    • GlaxoSmithKline
    • AstraZeneca
    • Roche
    • Novartis
    • ViiV Healthcare
    • Eisai
    • Hetero Labs
    • Mylan
    • Fujifilm Toyama Chemical
    • Sofinnova Partners

第13章 アナリストの全方位展望

目次
Product Code: ANV3935

REPORT HIGHLIGHT

Direct-acting Antiviral Drug Market size was valued at USD 28,409.32 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

The direct-acting antiviral (DAA) drug market focuses on medications that directly target and block the virus that causes hepatitis and HIV. These drugs work by interfering with the virus's ability to multiply, helping to clear the infection from the body. The drugs are important because they often have fewer side effects and work faster than older treatments. This makes them a preferred option for many patients. As awareness of these diseases grows, more people are seeking DAA drugs, leading to an increase in market demand. Overall, these drugs play a crucial role in improving health outcomes for those affected by viral infections.

Direct-acting Antiviral Drug Market- Market Dynamics

Growing awareness and screening programs for hepatitis and HIV.

The market for direct-acting antiviral (DAA) drugs is expanding due to several key drivers, including the increasing prevalence of hepatitis and HIV infections. As awareness of these diseases grows, more people are getting screened, leading to higher diagnosis rates. Improved healthcare access and education about these conditions are also contributing factors. Moreover, recent advancements in drug development have resulted in more effective treatments that act quickly, making them highly sought after.

The Centers for Disease Control and Prevention (CDC) reported that, in 2021, about 25% of people living with hepatitis B and C were diagnosed, highlighting the urgent need for effective therapies. This rising awareness and improved screening programs are crucial for managing and treating viral infections effectively. As a result, the demand for DAAs continues to grow, shaping the future of antiviral treatments.

Direct-acting Antiviral Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on Type segmentation, The NS5A Protein was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Hepatitis C virus was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution segmentation, Hospital Pharmacy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Direct-acting Antiviral Drug Market- Segmentation Analysis:

The Global Direct-acting Antiviral Drug Market is segmented based on Type, Indication, Route of Administration, Distribution, and Region.

The market is divided into three categories based on Type: NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA Polymerase. The NS5A Protein segment is the most prominent in the direct-acting antiviral drugs market. This is because NS5A inhibitors are highly effective in treating hepatitis C and are used in many successful treatment regimens. They help block the virus's ability to replicate and assemble, leading to better outcomes for patients. The growing demand for combination therapies that include NS5A inhibitors makes this segment dominant. As a result, NS5A Protein drugs are crucial for advancing hepatitis C treatment options and improving patient health.

The market is divided into four categories based on Indications: Hepatitis C Virus, HIV Infection/AIDS, Influenza, and Prophylaxis. The Hepatitis C virus segment is the most prominent in the direct-acting antiviral drug market. This is because hepatitis C affects millions of people worldwide, creating a strong demand for effective treatments. Direct-acting antivirals specifically designed for hepatitis C have shown high cure rates and are widely used. As awareness about the disease increases, more patients are seeking these treatments, making this segment dominant. Overall, hepatitis C drugs play a crucial role in improving health outcomes and reducing the disease's spread.

Direct-acting Antiviral Drug Market- Geographical Insights

The direct-acting antiviral (DAA) drug market is largest in North America, particularly the United States, where there is high demand for effective treatments for hepatitis C and HIV. Europe follows closely, with countries like Germany, France, and the UK investing in antiviral therapies. Asia-Pacific is a rapidly growing region, driven by increasing awareness and access to healthcare, especially in countries like China and India. Latin America also shows potential, with rising healthcare initiatives aimed at combating viral infections. The Middle East and Africa have a smaller market share but are gradually expanding due to improved healthcare infrastructure. Overall, North America leads, but other regions are making significant progress in the DAA market.

Direct-acting Antiviral Drug Market- Competitive Landscape:

The direct-acting antiviral (DAA) drug market is led by major players like Gilead Sciences and AbbVie, known for their effective treatments for hepatitis C and HIV. Other companies, including Merck and Bristol-Myers Squibb, also offer a variety of antiviral options, focusing on innovation and research to stay competitive. Many firms form partnerships to enhance their product lines and reach broader markets. As patents expire, generic manufacturers like Mylan and Hetero Labs enter the scene, providing lower-cost alternatives. The market is expanding globally, with a strong emphasis on making treatments affordable and accessible. Companies face regulatory challenges, needing extensive clinical trials for approval. Overall, the landscape is dynamic, marked by fierce competition and a commitment to improving patient care.

Recent Developments:

In September 2024, Cocrystal Pharma successfully advanced its oral pan-viral protease inhibitor, CDI-988, into Phase 1 multiple-ascending dose trials, which will evaluate the drug's safety, tolerability, and optimal dosing in healthy volunteers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • GlaxoSmithKline
  • AstraZeneca
  • Roche
  • Novartis
  • ViiV Healthcare
  • Eisai
  • Hetero Labs
  • Mylan
  • Fujifilm Toyama Chemical
  • Sofinnova Partners

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • NS3/4A Protease
  • NS5A Protein
  • NS5B RNA-Dependent RNA polymerase

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Hepatitis C Virus
  • HIV Infection/ AIDS
  • Influenza
  • Prophylaxis

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacy
  • Online Drug Store
  • Retail Pharmacy

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Direct-acting Antiviral Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Direct-acting Antiviral Drug Market Snippet by Type
    • 2.1.2. Direct-acting Antiviral Drug Market Snippet by Indication
    • 2.1.3. Direct-acting Antiviral Drug Market Snippet by Route of Administration
    • 2.1.4. Direct-acting Antiviral Drug Market Snippet by Distribution
    • 2.1.5. Direct-acting Antiviral Drug Market Snippet by Country
    • 2.1.6. Direct-acting Antiviral Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Direct-acting Antiviral Drug Key Market Trends

  • 3.1. Direct-acting Antiviral Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Direct-acting Antiviral Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Direct-acting Antiviral Drug Market Opportunities
  • 3.4. Direct-acting Antiviral Drug Market Future Trends

4. Direct-acting Antiviral Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Direct-acting Antiviral Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Direct-acting Antiviral Drug Market Landscape

  • 6.1. Direct-acting Antiviral Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Direct-acting Antiviral Drug Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. NS3/4A Protease
    • 7.1.3. NS5A Protein
    • 7.1.4. NS5B RNA-Dependent RNA polymerase

8. Direct-acting Antiviral Drug Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Hepatitis C Virus
    • 8.1.3. HIV Infection/ AIDS
    • 8.1.4. Influenza
    • 8.1.5. Prophylaxis

9. Direct-acting Antiviral Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intravenous
    • 9.1.3. Oral
    • 9.1.4. Subcutaneous
    • 9.1.5. Topical

10. Direct-acting Antiviral Drug Market - By Distribution

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacy
    • 10.1.3. Online Drug Store
    • 10.1.4. Retail Pharmacy

11. Direct-acting Antiviral Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Direct-acting Antiviral Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Direct-acting Antiviral Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Direct-acting Antiviral Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Direct-acting Antiviral Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Direct-acting Antiviral Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Direct-acting Antiviral Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. AbbVie
    • 12.2.3. Merck & Co.
    • 12.2.4. Bristol-Myers Squibb
    • 12.2.5. Johnson & Johnson
    • 12.2.6. GlaxoSmithKline
    • 12.2.7. AstraZeneca
    • 12.2.8. Roche
    • 12.2.9. Novartis
    • 12.2.10. ViiV Healthcare
    • 12.2.11. Eisai
    • 12.2.12. Hetero Labs
    • 12.2.13. Mylan
    • 12.2.14. Fujifilm Toyama Chemical
    • 12.2.15. Sofinnova Partners

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us